6826 — Shanghai Haohai Biological Technology Share News
0.000.00%
Last trade - 00:00- HK$3.59bn
- HK$1.47bn
- CNY2.47bn
Brief: Royal Bank Of Canada's Long Position In H-Shares Of Haohai Biological Falls To 4.58% - HKEX Filing
Brief: Royal Bank Of Canada's Long Position In H-Shares Of Haohai Biological Rises To 6.15% - Filing
Brief: Royal Bank Of Canada's Long Position In H-Share Of Shanghai Haohai Biological Rises To 5.06% - HFiling
Brief: Kabouter Management Buys H-Shares In Haohai Biological Technology - HKEX Filing
Brief: JPMorgan Chase & Co's Long Position In Haohai Biological Technology Falls To 4.65% - HKEX Filing
Brief: JPMorgan Chase & Co's Long Position In Haohai Biological Technology Rises To 6.02% - HKEX Filing
Brief: JPMorgan Chase & Co's Long Position In Haohai Biological Technology Rises To 5.32% - HKEX Filing
Brief: Shanghai Haohai Biological's H1 Net Profit Up 739.3% Y/Y
Brief: JPMorgan Chase & Co's Long Position In Haohai Biological Technology Falls To 4.31% - HKEX Filing
HK-listed Haohai Biological hits record high on robust earnings outlook
Brief: Shanghai Haohai Biological Technology Sees H1 Net Profit Up 699.2-808.2% Y/Y
China's medical cosmetology-related firms fall as crackdown looms
Brief: Shanghai Haohai Biological Technology Plans To Invest In Medical Technology Firm
FTSE Russell to include 11 stocks from China's STAR Market in global benchmarks
China's STAR Market stocks cede lofty valuations
Brief: Shanghai Haohai Biological Technology Says 9-Month Net Profit Attributable RMB 251 Mln
Brief: Shanghai Haohai Biological Technology To Issue 17.8 Mln A Shares At Price RMB89.23 Per A Share
Brief: Shanghai Haohai Biological Technology Sets Pricing For IPO In Shanghai Star Market
Brief: Shanghai Haohai Biological Technology Co Posts HY Profit Attributable Rmb182.57 Mln